Nuwellis Announces Findings From ULTRA-Peds Registry Study Examining Real-World Use Of Aquadex System In Children With AKI, Fluid Overload, Or Congenital Kidney Failure

Author: Benzinga Newsdesk | September 30, 2025 08:51am
ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment optionsResults highlight

ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment options

Results highlight life-threatening gaps in pediatric care and underscore Nuwellis' commitment to pediatric innovation and integrated cardio-renal care

MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced findings from the ULTRA-Peds registry, a multi-center observational study examining the real-world use of the Aquadex System in children with acute kidney injury (AKI), fluid overload, or congenital kidney failure.

The ULTRA-Peds registry enrolled 91 pediatric patients across eight U.S. centers, representing a comprehensive real-world dataset to date in this vulnerable population. Diagnoses included congenital heart disease (30%), end-stage renal disease (25%), and malignancy (14%).

Results demonstrated strong survival and procedural success: 92% of patients survived their Aquadex treatment course 66% survived to hospital discharge 86% of circuits completed their intended treatment course without interruption Heparin anticoagulation was associated with longer circuit duration compared to bivalirudin These findings show that Aquadex therapy is both feasible and well tolerated in critically ill children, a population with extremely limited treatment alternatives.

Posted In: NUWE